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Abstract Adrenocorticotropic hormone (ACTH) as a
treatment for proteinuria due to nephrotic syndrome (NS)
has re-emerged over the last decade. Current clinical data
are primarily limited to adults with treatment-resistant NS.
Largely unknown to today’s clinicians is the existence of
early clinical studies, following ACTH’s introduction in
the late 1940s, showing sustained proteinuria response in
idiopathic NS in predominantly pediatric, treatment-naı¨ve
patients. Before ACTH, patients suffered severe edema and
high mortality rates with no reliable or safe treatment.
ACTH dramatically altered NS management, initially
through recognition of diuresis effects and then through
sustained proteinuria remission. This review synthesizes
early clinical literature to inform current NS patient man-
agement. We undertook a MEDLINE search using MeSH
terms ‘‘adrenocorticotropic hormone’’ and ‘‘nephrotic
syndrome,’’ with limits 1945–1965 and English. Sixty
papers totaling 1137 patients were found; 14 studies (9
short-term, five long-term, N = 419 patients) met inclusion
criteria. Studies were divided into two groups: short-term
(B28 days) and long-term ([5 weeks; short-term initial
daily treatment followed by long-term intermittent)ACTH
therapy and results were aggregated. An initial response,
defined as a diuresis, occurred in 74 % of patients/treat-
ment courses across nine short-term ACTH studies.
Analyzed in eight of these studies, proteinuria response
occurred in 56 % of patients/treatment courses. Across five
long-term ACTH studies, proteinuria response was shown
in 71 % of patients and was sustained up to 4.7 years
following treatment. The inventory and re-evaluation of
early clinical data broadens the evidence base of clinical
experiences with ACTH for implementation of current
treatment strategies and aiding the design of future studies.
Keywords Adrenocorticotropic hormone  Nephrotic
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Introduction
Adrenocorticotropic hormone (ACTH) re-emerged over the
last decade as a treatment for nephrotic syndrome (NS)
following studies in Europe and the United States.
Proteinuria reduction was shown using a synthetic ACTH
intramuscular depot formulation (tetracosactide), available
in Europe but not the US [1, 2]. Later, a randomized,
controlled trial compared treatment with this compound
administered twice weekly for 1 year to alternating months
of methylprednisolone and cyclophosphamide or chlo-
rambucil for 6 months (the Ponticelli regimen). This study
showed comparable high remission rates in patients with
idiopathic membranous nephropathy with both treatments
[3]. More recently, the pituitary extract-derived compound
H.P. Acthar Gel (repository corticotropin injection;
Mallinckrodt ARD Inc., Hazelwood, MO) has significantly
reduced proteinuria in some patients with NS with a variety
of histologic patterns [4–9]. These reports studied rela-
tively small, heterogeneous patient groups for limited time
periods and most patients had treatment-resistant NS prior
to initiation of Acthar Gel. Almost all the subjects were
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adults with either membranous nephropathy or focal seg-
mental glomerulosclerosis. Thus, current clinical data
examining ACTH treatment of NS are very limited, espe-
cially in pediatric patients.
The early ACTH clinical studies are largely unknown to
today’s practicing clinician. Yet, the majority of clinical
studies that evaluated ACTH treatment for NS were con-
ducted in the 1950s using a compound purified from
pituitary extract. These early studies evaluated predomi-
nantly pediatric, treatment-naı¨ve patients with idiopathic
NS who likely would have been diagnosed with minimal
change disease (MCD). Prior to the emergence of ACTH in
the late 1940s, there was no reliable treatment that pro-
vided symptom relief or remission. Patients suffered from
generalized, severe edema that could remain for months,
often resulting in semi-incapacity to complete disability.
They were extremely vulnerable to infection and the
mortality rate was as high as 40–71 % within approxi-
mately 4–5 years of NS onset [10–12]. Treatments, such as
intentional infection with measles or malaria, infusion of
concentrated serum albumin, nitrogen mustard and mer-
curial diuretics yielded variable results and were associated
with significant risks [13–16].
The introduction of ACTH (purified from a pituitary
extract) dramatically altered NS management, initially
most visibly by providing relief from gross edema through
diuresis and then with longer treatment courses enabling
sustained proteinuria remission [14, 17]. Prolonged,
intensive ACTH or steroid therapy improved survival
compared to historical control patients; the mortality rate
declined to approximately 20–23 % [11, 12, 18]. The initial
ACTH investigations across a broad range of diseases,
including NS, are described in the Proceedings of the First
Clinical ACTH Conference, held in 1949 in Chicago [19,
20]. Studies examining ACTH therapy for NS were pub-
lished throughout the 1950s, including case studies and
large patient cohorts [10, 13–17, 21–40]. ACTH was lar-
gely replaced with the synthetic oral steroid prednisone in
the 1960s due to its greater ease of administration and more
reliable availability [10]. No comparative effectiveness
clinical trials were ever conducted. Additionally, at that
time the possible differing mechanisms of action between
ACTH and steroids or that ACTH may have steroid-inde-
pendent pathways were not understood. Treatment of
infantile spasms (IS) was an exception to the shift toward
steroid treatment. Neurologists continued to use ACTH as a
primary treatment for IS since the initial 1958 report by
Sorel and Dusaucy-Bauloye [41].
A critical need remains for effective treatment for
patients with NS who are not responsive to the standard
regimen of orally administered steroid without the renal
and extra-renal toxicities often associated with chronic use
of current therapies [42]. Analysis of the early clinical
studies addresses an important need in expanding clinical
experience and understanding ACTH treatment in NS. The
aim of the current retrospective review and analysis is to
broaden the evidence base underlying implementation of
current ACTH therapy and aid in the design of future
robust studies. The current systematic review examines the
largest patient population receiving ACTH treatment
available to date and examines three periods within the
clinical development of ACTH treatment. First, the effects
of short-term, daily ACTH on diuresis with edema reso-
lution, the clinical response focus when ACTH was first
introduced, were examined. This initial treatment response
led early investigators to hypothesize that ACTH was a
diuretic. Second, following the realization that ACTH had
an important treatment role beyond diuresis, the focus
shifted to the effects of short-term ACTH on proteinuria.
Third, studies evaluated the effects of long-term intermit-
tent ACTH therapy on sustained proteinuria response.
Methods
MEDLINE was searched using the MeSH terms ‘‘adreno-
corticotropic hormone’’ and ‘‘nephrotic syndrome,’’ with the
limits 1945 (era of ACTH introduction) to 1965 (ACTH was
largely replaced by synthetic oral steroids by this time) and
English. Studies also were selected from reference lists of
reviewed papers and author K.V.L.’s historical collection.
Study selection is shown in Fig. 1. In studies that examined
ACTH and steroid treatment, only ACTH-related data were
considered. Studies that focused on acute glomerulonephritis
with gross hematuria were excluded. When multiple papers
used overlapping patient groups, only one was included.
Inclusion criteria included:[5 patients treated; report-
ing on the clinical response of diuresis and edema resolu-
tion; proteinuria (defined quantitatively or semi-
quantitatively); and tolerability. Outcomes were tabulated
using counts and percentages. Seven of the nine short-term
studies and all five long-term studies reported treatment
outcomes by number of patients. Two short-term studies
reported outcomes by number of treatment courses. The
aggregation of proteinuria response and diuresis data
among short-term studies combined the number of patients
from seven studies and the number of treatment courses
from ywo studies. Tolerability was characterized descrip-
tively. Short-term treatments were defined as daily ACTH
for B4 weeks. Long-term treatments had an initial daily
induction regimen followed by intermittent dosing sched-
ules for C5 weeks beyond the initial treatment course.
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Results
Sixty papers with 1137 patients were identified (on-line
Table). Inclusion/exclusion criteria were met by 14 studies
that included 419 patients. Nine studies with 330 patients
examined clinical responses (diuresis with edema resolu-
tion) to short-term ACTH. Eight of these studies included
data on proteinuria response in 225 patients. Five studies
with 89 patients reported sustained proteinuria response
with long-term treatment. The patients were predominantly
pediatric (88 %; 341/388 with ages given) with
age B20 years [10, 13, 14, 17, 31–40]. Report of protein-
uria response was semi-quantitative, including marked
reduction, absence or trace level, within normal limits and
1? level.
Short-term ACTH therapy
Short-term ACTH treatment results for diuresis
response and proteinuria are summarized in Table 1
[10, 14, 31–37]. ACTH dose ranged from 20 mg/day to
160 mg/day, with one protocol using the regimen of
150–200 mg/m2/day [35]. Mean treatment duration for a
single treatment course was approximately 12 days,
ranging 4–28 days. Patients who relapsed following
cessation of short-term treatment or who did not
respond adequately often received additional short-term
ACTH courses [10, 14, 31–36].
Diuresis with edema resolution was the key clinical
outcome in the earliest studies of short-term ACTH and
ACTH dose was quickly tapered or discontinued following
diuresis onset [14, 37]. The nine short-term ACTH treat-
ment studies reported diuresis with edema resolution in
74 % (265/356) of patients/treatment courses [14, 31–36].
Compared with the six short-term ACTH studies showing
diuresis in C75 % of patients, the three studies that
reported diuresis in\75 % of patients had shorter treat-
ment duration, courses of 4–6 days, or lower ACTH
dosage, 20–25 mg/day (Table 1). Onset of diuresis occur-
red either during or within a few days following the ces-
sation of ACTH treatment. Diuresis was usually temporary,
with the majority of patients relapsing within 1 month [33].
The eight short-term ACTH treatment studies that
reported proteinuria showed a proteinuria response in 56 %
(156/279) of patients/treatment courses. Using the more
restrictive definition of proteinuria absence, 50 % (139/
279) of patients/treatment courses showed a proteinuria
response. The duration of treatment effects on proteinuria
were described as transient for the majority of patients,
lasting a few days to a few months following ACTH ces-
sation, or were not examined [10, 14, 31, 33–35]. A study
at the upper end for treatment duration (up to 21 days) and
ACTH dose (160 mg/day) found 12/22 (54 %) patients
who had shown proteinuria absence following C1 courses
of ACTH had sustained proteinuria remission at
their C12 month post-treatment assessment [32].
Records identified through 
MEDLINE search
(n=65)
Additional records identified 
through other sources
(n=56)






Full-text articles assessed for
eligibility
(n=60)a 
Full-text articles excluded (n=46)
<5 patients treated (n=16)
Mixed ACTH, steroid or other treatment courses (n=7)
Inadequate treatment regimen detail (n=4)
Overlapping patients with another included study (n=11)
Acute glomerulonephritis/gross hematuria (n=2)





Fig. 1 Identification and selection of early clinical ACTH studies. aThe complete list of the 60 articles assessed for eligibility is available in the
on-line table. ACTH adrenocorticotropic hormone
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Long-term ACTH therapy
Long-term ACTH treatment results are summarized in
Table 2 [13, 17, 38–40]. All regimens included an initial
short-term daily ACTH treatment course. The ACTH
intermittent regimen doses ranged from 100 to
200 mg/day, with the exception of one protocol that used
1 mg/lb/day [40]. The regimens of four studies included
intermittent ACTH treatment for three consecutive days
repeated weekly for up to 24 months. One study used
long-term daily ACTH treatment for up to 19 months as
maintenance therapy [38]. In the remaining study, the
initial ACTH treatment course was followed by daily
ACTH treatment at 1 mg/lb/day until absence of
Table 1 Proteinuria and diuresis response during short-term ACTH therapy for nephrotic syndrome
















10 (71) 11/14 (79) response
4/14 (29) absence
3/10 (30) up to 10 moi
7/10 (70) B4 moi
Rapoport [36] 34 \8 (34) 40–150 mg/d
8–12 d
28 (82) 12/12e (100) response 13/28 (72) up to 18 moi
Kramer [14] 12 B18 (12) 50–100 mg/d up to 125 mg/
d
8–13 d
9 (75) 9/12 (75)
absence/trace
1/12 (8) 12 moj
7/12 (58) 1–9 moj
Metcoff [35] 45 \12 (45) 150–200 mg/m2/d
8–10 d
34 (75) 3/12f (25) response NA
Riley [37] 50 \18 (49) 60 mg/d (age\ 4)
80 mg/d (age 4–9)
100 mg/d (age[ 9)
10 d
41/63c (65) NA 111/140 (79) B3 moi,k
Rance [10] 88 B18 (88) 20–50 mg/db
4–28 d
75/109c (69) 44/109g (40) absence
25/33h (76) absence
NA
Baskin [31] 18 B18 (18) 50–100 U/d
7–14 d
15 (83) 17/18 (94) response
7/18 (41) absence
NA





25/30d (83) 22/38 (58) absence 12/22 (54)
C12 moj




28 (90) 13/31 (42) response 4/31 (13)[2 yrj
Total patients showing response
N (%)
265/356 (74) 156/279 (56)
ACTH adrenocorticotropic hormone, d day(s), mo month(s), NA not available, yr year(s)
a Age was not specified for the subset of patients who received ACTH treatment
b 1 or more patients received one or more courses of ACTH treatment by intravenous infusion
c Percentage of ACTH treatment courses
d 30/38 patients presented with edema
e 12/34 patients had assessment of proteinuria
f 12/45 patients completed proteinuria assessment pre- and post-ACTH therapy
g Number of courses with edema present pre-treatment
h Number of courses without edema at pre-treatment
i Diuresis with edema resolution response duration
j Proteinuria response duration
k Treatment courses included ACTH and/or cortisone
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albuminuria for 1–2 weeks [40]. Treatment then shifted to
an intermittent, every-other-day regimen with ACTH
increased to 1.2 mg/lb/day if no response was shown by
3 weeks, followed by reduction in ACTH dose over
several weeks. In this treatment protocol, if albuminuria
increased during the intermittent regimen, the dose or
frequency of ACTH was doubled or increased to the
initial treatment dose.
Sustained proteinuria response was examined in the five
long-term studies. Evaluation of proteinuria response dur-
ing long-term ACTH or combined long-term ACTH and
post-treatment follow-up showed proteinuria response in
71 % (63/89) of patients [13, 17, 38, 40]. The two studies
that reported proteinuria response post-treatment showed
61 % (19/31) of patients had sustained proteinuria response
for up to 26 months [39, 40].
Patient follow-up ranged from 1 month to 4.7 years [13,
17, 38–40]. In a study of 25 patients, sustained proteinuria
response following ACTH cessation was shown in 14
patients for a mean of 9.6 months and another nine patients
showed continued proteinuria response during their ongo-
ing ACTH intermittent regimen [40]. A study of 38
patients, primarily adults, found proteinuria response in 18
(47 %) patients following the initial course of ACTH.
Twelve (67 %) of these patients showed sustained pro-
teinuria response during the long-term ACTH regimen or
post-ACTH treatment for up to 4.7 years [38]. An addi-
tional two patients who did not show proteinuria response
following the initial ACTH course did show proteinuria
response after long-term (13 and 14 months) intermittent
ACTH treatment at the 1- and 3-year evaluations. Fol-
lowing 5–8 weeks of an intermittent ACTH regimen, 5/6
(83 %) patients showed sustained proteinuria response at
6–26 months following ACTH cessation [39]. Two studies
reported 9/9 and 11/11 patients showed sustained protein-
uria response following long-term ACTH without provid-
ing the specific treatment duration versus post-treatment
assessment [13, 17].
Tolerability
The early clinical studies noted a worsening of edema at
initiation of ACTH therapy, prior to diuresis [32–34].
Although not yet well known at the time, we can now
conclude that the worsening of edema was likely due to
fluid retaining effects via the steroidogenic effects of
ACTH. Side effects associated with hyperadrenocorticism,
including characteristics of Cushing’s syndrome, were
described during short-term, high-dose (ranging from 100
to 160 mg/day) daily ACTH treatment, but resolved fol-
lowing ACTH cessation [14, 32, 33, 36]. Additionally,
freckling was reported in nearly all patients in one study
[17]. Long-term intermittent ACTH treatment studies
described less pronounced hyperadrenocorticism side
effects [17, 38, 40].
Discussion
ACTH transformed the treatment of patients with NS in the
late 1940s through the 1950s. There was a dramatic drop in
mortality from as high as 40–71 % before the introduction
of ACTH to 23 to 25 % by 1958 [11, 12, 18]. Following the
first clinical use of ACTH in NS by Edith Farnsworth in
1948, short-term ACTH regimens with daily high-dose
treatment targeted at diuresis were introduced to bring
relief and improve quality of life in greatly suffering ede-
matous patients [19, 20].
In the current examination of the early clinical literature,
74 % of patients achieved a diuresis in response to one or
more short-term ACTH courses. However, proteinuria
completely resolved in only 54 % of the historical patients
who received short-term treatment. This lower response
rate as compared with current regimens is likely due to the
briefer treatment course. The brevity of the diuresis and the
variable effect on proteinuria led some early investigators
to consider ACTH a diuretic without effect on the core
pathophysiologic alterations of NS. A report from the
International Study of Kidney Diseases in Children
(ISKDC) described time to response (here defined as pro-
teinuria resolution) for patients with MCD treated with
prednisone [43]. A similar response rate was seen in
patients treated with prednisone for 1–2 weeks as was seen
in the short-term ACTH experience. In the short-term
ACTH studies, a dose–response association was recog-
nized. Examination of patient outcomes relative to treat-
ment duration showed that treatment \8 days was
ineffective whereas 83 % of patients showed loss of
edema, proteinuria or both when treatment was C18 days
[10]. Similarly, it was stated that the proteinuria response
was more pronounced with 4 weeks as compared to
1–2 weeks of treatment [17].
A key goal of long-term ACTH treatment was to induce
a proteinuria response in patients who had not responded to
short-term therapy, in modern terms to overcome steroid
resistance, and the long-term studies showed a greater
percentage of patients achieving proteinuria remission [38].
These early findings are consistent with modern treatment
regimens using longer-term administration schedules.
Some patients who were resistant when treated short-term
then responded to a longer treatment regimen. That the
proteinuria response rate of 54 % in short-term studies
improved to 71 % during long-term treatment supports an
important modern treatment indication for ACTH in
patients who are steroid resistant.
40 J Nephrol (2017) 30:35–44
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The transient proteinuria response during the early
short-term clinical trials also led some clinical researchers
to consider whether longer ACTH treatment could modify
the course of NS and produce a sustained proteinuria
remission [31]. ACTH regimens evolved to longer duration
of continuous treatment; repeated intermittent treatment
cycles with short intervals of no treatment; and the inclu-
sion of additional ACTH courses in patients who had
already achieved a diuresis [13, 32, 44–46]. Barnett and
colleagues hypothesized in 1954 that proteinuria in patients
with NS was due to increased permeability of the
glomerular capillary wall to proteins such as albumin [21].
Following an ACTH treatment study in 10 children with
NS in which glomerular filtration was also serially evalu-
ated, Barnett and colleagues concluded that the primary
effect of ACTH treatment is the shift toward normal of
glomerular permeability to albumin and other plasma
proteins.
Long-term intermittent regimens treated patients with
ACTH from 5 weeks to 2 years beyond the initial short-
term daily ACTH regimen with follow-up of patient out-
comes up to 4 years post-ACTH therapy [13, 17, 38–40].
In the current examination of the early clinical studies, the
long-term study that primarily examined adults showed
37 % were maintained in long-term remissions during
ACTH treatment and/or post-treatment up to 4.7 years
[38]. Among the four long-term studies that included
children, C92 % of patients were maintained in remissions
during ACTH treatment [13, 17, 39, 40]. In one study,
83 % of patients showed sustained proteinuria response up
to 26 months post-treatment and in another study, 56 % of
patients showed sustained proteinuria response up to
18 months post-treatment [39, 40]. The high rate of sus-
tained remissions in children receiving longer duration
formulation ACTH treatment supports the use of ACTH
therapy in patients who are steroid dependent (SD) or
frequently relapsing (FR), two important modern treatment
needs.
The multinational, collaborative work of the ISKDC
during the 1970s resulted in histopathologic classification
(utilizing the newly introduced technique of percutaneous
kidney biopsy) and the clinical characterization system
based on steroid response. The current review found 71 %
of patients achieved proteinuria response with long-term
intermittent ACTH treatment, which is consistent with later
reports of response rates with longer-term steroid treatment
[43]. Patients included in long-term ACTH treatment to
maintain proteinuria remission would fit later definitions of
SD, steroid resistant (SR) and FR. In one long-term study,
patients who experienced C1 exacerbations were placed on
intermittent or continuous ACTH therapy [17]. Among 34
exacerbations, 18 patients were re-treated 1–6 times and
the proteinuria response to retreatment with ACTH was
comparable to the initial treatment response [17]. In
another long-term study, continuous treatment was initiated
in patients who relapsed following the initial treatment
course [40]. Among the 12 patients, there was an average
of four failed intermittent treatment courses before con-
tinuous treatment was implemented, resulting in sustained
remissions [40].
Different ACTH formulations, and purification and
standardization protocols during the 1950s (with the
potential for impurities) likely led to more variability in
patient outcomes and side effects than would be expected
with the currently available, FDA approved, highly purified
Acthar Gel formulation. Of the eight studies that reported
their ACTH source, four named Armour Laboratories (a
precursor of Acthar HP gel in the literature) [34–36, 39],
two stated the National Drug Company [17, 38], and one
each identified the Medical Research Council [32] and
Connaught Laboratories/Nordic Biochemicals Limited
[10]. Comparison of dosages is also problematic. In some
cases, the active ingredient was quantified in mg or
mcg/mL, whereas in other products it was characterized by
biologic potency or activity in U/mL. Acthar Gel is
approved by the FDA based on potency (U/mL). Although
it is possible to qualitatively compare efficacy of Acthar
Gel (dosed in U/mL) with that of historical ACTH prepa-
rations (dosed in mg or mcg/mL) in a given indication, it is
not possible to quantitatively compare the specific dosing
regimens.
These early clinical studies focused primarily on chil-
dren. The most common diagnosis in current nosology was
likely MCD, as indicated by the high percent of prompt
remissions that were observed. Focal segmental glomeru-
losclerosis was probably present in some patients with
short-term treatment resistance. Current clinical studies
examining ACTH treatment in children with NS are scarce,
yet the early clinical literature suggests ACTH may be very
beneficial for these patients [47]. Additional effective,
tolerable treatment options are of particular need among
children with NS who are nonresponsive to or unable to
tolerate steroid or other first- or second-line treatments.
A central question for today’s clinicians is which patient
subgroups respond to ACTH treatment and what underlies
differential responsiveness. One possibility relates to the
total cumulative ACTH dose needed for a clinical response
and the balance between cumulative dose, treatment
duration, and potential side effects in patient subgroups.
For example, among patients with idiopathic membranous
nephropathy, those receiving greater cumulative dose
ACTH gel (2800 U) showed greater proteinuria reduction
compared with lower cumulative doses (880 and 1760 U)
[7]. Although the early clinical studies did not provide
sufficient details to determine cumulative dose, the differ-
ences between short-term daily and long-term intermittent
J Nephrol (2017) 30:35–44 41
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ACTH regimens in producing sustained proteinuria
response supports that such a balance is important for
optimal patient outcomes.
One early clinical study noted freckling, a probable mel-
anocyte effect, in nearly all patients, an early indication of a
possible non-steroid pathway of action for ACTH [17]. A
recent focus in understanding patient responsiveness to
ACTH therapy in NS is the mechanism of action of ACTH
through the interaction of ACTH with melanocortin recep-
tors (MCRs) and their steroid dependent and independent
pathways [48–50]. Steroid-independent effects may occur
through MC1R [51, 52]. ACTH in an animal model of pro-
gressive renal tubulointerstitial injury has shown suppres-
sion of tubulointerstitial inflammation, tubular atrophy, and
fibrosis through anti-inflammatory effects mediated by
MC1R on tubular epithelial cells [51]. MC1Rs have been
shown in podocytes, glomerular endothelial cells, and
mesangial cells, and an MC1R agonist resulted in signifi-
cantly reduced proteinuria in the passive Heymann nephritis
animal model [52]. Such steroid-independent mechanisms of
action may provide an explanation for ACTH efficacy in
steroid-resistant patients (Fig. 2).
The current systematic review has several limitations.
Indexing of published studies was not exhaustive during
the 1950s, resulting in some papers being unavailable for
review. Some papers used a discussion format and did not
provide comprehensive clinical information. Modern
nomenclature was not available for patient diagnoses and
categorization as there was no clinical classification, such
as ‘‘steroid responsive,’’ or histological classifications as
are used today. Despite the absence of modern terminol-
ogy, the detailed clinical descriptions in the selected
manuscripts enables a useful analysis of this experience.
Potential risk of bias in the publication of early clinical
studies could not be formally assessed.
Conclusion
The potential of ACTH to produce sustained proteinuria
response in idiopathic NS was shown at its introduction in
the 1950s. This historical experience, which provides the
largest population of patients with NS treated with ACTH
to date and broadens the evidence base of clinical experi-
ence with ACTH, has the following contemporary impli-
cations. Daily ACTH can be effectively substituted for
daily prednisone for the initial treatment of newly pre-
senting patients with NS as well as for the treatment of
relapses in patients already known to be steroid responsive.
This approach with ACTH treatment has already been
Fig. 2 Putative mechanisms of




melanocyte, NK natural killer,
R receptor Adapted from Ref.
[49], page 141, Copyright 2014,
with permission from Elsevier
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shown to be very useful for patients who are not able to
tolerate oral steroid treatment [47]. Patients with chronic
gastritis, for whom oral steroid administration is relatively
contraindicated, could also benefit from the parenteral
administration of ACTH. Determining whether this regi-
men would result in a higher percentage of treatment
responses or more sustained remissions compared with the
current standard regimen will require an appropriately
powered clinical trial.
The historical data suggest a role for ACTH therapy for
the more problematic patients with SD, FR and SR pat-
terns. Longer-term intermittent ACTH courses were well
tolerated and induced remissions at a higher rate than
shorter regimens as well as sustained long-term remissions
for many patients. With current regimens, these patients
suffer significant cumulative steroid toxicity and are often
exposed to the toxicities of intensive immunosuppressive
therapies. A clinical trial of ACTH treatment of SD and FR
patients is currently recruiting and a clinical trial for the
treatment of SR patients is in the final stage of planning.
Demonstration of ACTH responsiveness in steroid-resis-
tant children (as demonstrated in adults) would represent a
significant advance in therapeutics [4–7].
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